On the basis of these observations, we thus speculate that BVZ could have an effect on cancer cells, and that ID1-overexpressing cells may have reduced dependence on VEGF/VEGFR2 signaling, potentially contributing to an attenuation of the efficacy of BVZ. The gene discussed is ID1; the disease is cancer.